Palatin Technologies, Inc. (PTN)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Palatin Technologies, Inc. (PTN) trades at $13.04 with AI Score 43/100 (Grade C). Palatin Technologies, Inc. is a biopharmaceutical company specializing in targeted receptor-specific therapeutics. Market cap: $339.12M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for PTN: PTN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PTN against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PTN: the 1 perspectives are evenly split.
Palatin Technologies, Inc. (PTN) Healthcare & Pipeline Overview
Palatin Technologies, Inc. is a biopharmaceutical firm focused on melanocortin receptor (MCr) therapeutics, highlighted by Vyleesi for hypoactive sexual desire disorder. With a strong gross margin of 99.2%, Palatin navigates the competitive biotech landscape while developing treatments for inflammatory and cardiovascular diseases.
What Is the Investment Thesis for PTN?
Palatin Technologies presents a high-risk, high-reward investment profile. The company's lead product, Vyleesi, addresses a significant market in women's health, but its commercial success is still evolving. The pipeline of melanocortin receptor agonists, particularly PL8177 for IBD and PL9643 for dry eye disease, represents potential growth catalysts. The company's high gross margin of 99.2% indicates strong pricing power, but its negative profit margin of -107.4% highlights the need for improved cost management. Upcoming clinical trial results for PL8177 and PL9643 will be critical in determining the company's future prospects. The company's market capitalization of $0.61 billion reflects investor sentiment regarding its potential and risks.
Based on FMP financials and quantitative analysis
PTN Key Highlights
- Vyleesi is Palatin's lead product, approved for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Gross margin of 99.2% demonstrates strong pricing power in its market.
- Developing PL8177, an oral selective MC1r agonist peptide, has completed Phase I clinical trial for inflammatory bowel diseases.
- PL9643, a peptide melanocortin agonist, is being developed for anti-inflammatory ocular indications, such as dry eye disease.
- Market capitalization of $0.61 billion reflects investor sentiment.
Who Are PTN's Competitors?
PTN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.59M | 54 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| ABCL AbCellera Biologics Inc. | $5.24 | -0.57% | 2B | 76 |
| TLX Telix Pharmaceuticals Limited | $9.56 | +1.16% | 4B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $18.23 | +6.64% | 2B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | 3B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PTN's Key Strengths?
- Approved product (Vyleesi) with established market presence.
- Promising pipeline of melanocortin receptor agonists.
- High gross margin.
- Experienced management team.
What Are PTN's Weaknesses?
- Limited financial resources.
- Negative profit margin.
- Reliance on Vyleesi for revenue.
- Small number of employees.
What Could Drive PTN Stock Higher?
- Phase II clinical trial results for PL8177 in inflammatory bowel disease (IBD) expected in Q4 2026.
- Phase II clinical trial results for PL9643 in dry eye disease expected in Q1 2027.
- Continued commercialization and market expansion of Vyleesi.
- Potential partnerships and licensing agreements for pipeline products.
What Are the Key Risks for PTN?
- Competition from other pharmaceutical companies in the HSDD, IBD, and dry eye disease markets.
- Regulatory hurdles and delays in the approval of pipeline products.
- Unfavorable clinical trial results for PL8177 and PL9643.
- Reliance on Vyleesi for revenue and the need to diversify the product portfolio.
- Limited financial resources and the need to raise additional capital.
What Are the Growth Opportunities for PTN?
- Vyleesi Market Expansion: Vyleesi holds potential for increased market penetration within the HSDD market. The company can expand its reach through targeted marketing campaigns, partnerships with healthcare providers, and exploring new indications or formulations. The global market for sexual dysfunction treatments is projected to reach billions of dollars, offering substantial growth opportunities for Vyleesi.
- PL8177 for Inflammatory Bowel Disease: The development of PL8177 for IBD represents a significant growth opportunity. IBD affects millions worldwide, and there is a need for more effective and convenient treatments. Positive Phase II clinical trial results for PL8177 could lead to partnerships with larger pharmaceutical companies and accelerate its path to market. The IBD therapeutics market is estimated to be worth billions of dollars.
- PL9643 for Dry Eye Disease: PL9643 targets the large and growing dry eye disease market. Dry eye affects millions of people and is driven by factors such as aging, increased screen time, and environmental conditions. Successful clinical trials and regulatory approval for PL9643 would position Palatin as a key player in the ophthalmology space. The dry eye disease market is projected to reach billions of dollars in the coming years.
- Cardiovascular Programs: Palatin's cardiovascular programs, including PL3994 and PL5028, offer long-term growth potential. Cardiovascular diseases are a leading cause of death worldwide, and there is a need for novel therapies to address conditions such as heart failure and fibrosis. These programs are in earlier stages of development, but successful clinical trials could lead to significant value creation.
- Partnerships and Licensing: Palatin can pursue strategic partnerships and licensing agreements to accelerate the development and commercialization of its pipeline products. Collaborating with larger pharmaceutical companies can provide access to resources, expertise, and distribution networks. Licensing out certain assets can generate upfront revenue and milestone payments, providing financial flexibility to invest in other programs.
What Opportunities Does PTN Have?
- Expansion of Vyleesi market share.
- Positive clinical trial results for pipeline products.
- Strategic partnerships with larger pharmaceutical companies.
- Out-licensing of intellectual property.
What Threats Does PTN Face?
- Competition from other pharmaceutical companies.
- Regulatory hurdles and delays.
- Unfavorable clinical trial results.
- Product liability risks.
What Are PTN's Competitive Advantages?
- Proprietary melanocortin receptor (MCr) agonist technology.
- Patent protection for Vyleesi and other pipeline products.
- Clinical data supporting the efficacy and safety of its therapeutics.
- Established relationships with key opinion leaders and healthcare providers.
What Does PTN Do?
Palatin Technologies, Inc., founded in 1986 and headquartered in Cranbury, New Jersey, is a biopharmaceutical company dedicated to developing targeted, receptor-specific therapeutics. The company's primary focus is on melanocortin receptor (MCr) agonists, with its lead product, Vyleesi, approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi represents a significant advancement in women's health, offering an on-demand treatment option. Beyond Vyleesi, Palatin is actively developing a pipeline of novel therapeutics. PL8177, an oral selective MC1r agonist peptide, has completed Phase I clinical trials for inflammatory bowel diseases (IBD), showcasing the company's commitment to addressing unmet needs in gastroenterology. PL9643, a peptide melanocortin agonist targeting multiple MCrs, including MC1r and MC5r, is being developed for anti-inflammatory ocular indications, such as dry eye disease. The company is also exploring melanocortin peptides for diabetic retinopathy. In the cardiovascular space, Palatin is advancing PL3994, a natriuretic peptide receptor (NPR)-A agonist, and PL5028, an NPR-A and NPR-binder, for treating cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin's research and development efforts span multiple therapeutic areas, reflecting its commitment to innovation and addressing significant medical challenges.
What Products and Services Does PTN Offer?
- Develops targeted receptor-specific therapeutics.
- Focuses on melanocortin receptor (MCr) agonists.
- Markets Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Develops PL8177 for the treatment of inflammatory bowel diseases (IBD).
- Develops PL9643 for anti-inflammatory ocular indications, such as dry eye disease.
- Develops melanocortin peptides for diabetic retinopathy.
- Develops PL3994 and PL5028 for cardiovascular indications.
How Does PTN Make Money?
- Develops and commercializes pharmaceutical products.
- Generates revenue through product sales (Vyleesi).
- Out-licenses intellectual property and technologies.
- Forms strategic partnerships with other pharmaceutical companies.
What Industry Does PTN Operate In?
Palatin Technologies operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and the potential for significant returns on successful products. The market for women's health products, including treatments for sexual dysfunction, is growing, driven by increased awareness and demand for effective therapies. The inflammatory bowel disease (IBD) and dry eye disease markets also represent significant opportunities for companies developing novel treatments. Palatin competes with larger pharmaceutical companies and other biotech firms in these areas.
Who Are PTN's Key Customers?
- Premenopausal women with hypoactive sexual desire disorder (HSDD).
- Patients with inflammatory bowel diseases (IBD).
- Patients with dry eye disease.
- Potential partners: pharmaceutical companies for licensing deals.
PTN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying has sparked optimism, suggesting confidence in the company's future.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their pipeline.
- Analysts are noting increased interest in the therapeutic areas Palatin operates, indicating a growing market for their products.
- Recent partnerships and collaborations have been viewed favorably, enhancing credibility and potential for revenue growth.
Bear Case
- Concerns have been raised about the company's ability to secure funding for ongoing projects, leading to uncertainty.
- Market perception remains cautious, with some investors questioning the viability of their drug candidates based on past performance.
- Negative sentiment has emerged from discussions around regulatory hurdles that could delay product launches.
- Recent news cycles have highlighted competitive pressures, with emerging therapies posing significant challenges to Palatin's market position.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PTN Latest News
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Mar 25, 2025
-
Earnings Scheduled For February 13, 2025
benzinga · Feb 13, 2025
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Oct 14, 2024
-
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
benzinga · Feb 28, 2024
PTN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PTN.
Price Targets
Wall Street price target analysis for PTN.
PTN MoonshotScore
What does this score mean?
The MoonshotScore rates PTN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Earnings Scheduled For February 13, 2025
12 Health Care Stocks Moving In Monday's After-Market Session
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Leadership: Carl Spana
CEO
Carl Spana has served as the CEO of Palatin Technologies, Inc. since 2000. He has extensive experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. Prior to joining Palatin, he held leadership positions at various pharmaceutical companies. His expertise spans preclinical and clinical development, regulatory affairs, and business development. He has been instrumental in guiding Palatin through various stages of growth and development.
Track Record: Under Carl Spana's leadership, Palatin Technologies has achieved several key milestones, including the FDA approval of Vyleesi. He has overseen the development of the company's pipeline of melanocortin receptor agonists and has forged strategic partnerships to advance its programs. He has also successfully navigated the challenges of raising capital and managing the company's financial resources. His strategic vision has been instrumental in positioning Palatin as a leader in the field of melanocortin therapeutics.
PTN Healthcare Stock FAQ
What does Palatin Technologies, Inc. do?
Palatin Technologies, Inc. is a biopharmaceutical company that develops targeted receptor-specific therapeutics, primarily focused on melanocortin receptor (MCr) agonists. Its lead product, Vyleesi, is approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The company also has a pipeline of products in development for inflammatory bowel diseases (IBD), dry eye disease, diabetic retinopathy, and cardiovascular conditions. Palatin aims to address unmet medical needs by developing innovative therapies that target specific receptors in the body.
What do analysts say about PTN stock?
Analyst coverage of Palatin Technologies, Inc. is limited, reflecting its small market capitalization and early-stage pipeline. The consensus view is that PTN is a high-risk, high-reward investment opportunity. Key valuation metrics include the potential peak sales of Vyleesi and the value of its pipeline products. Growth considerations include the successful completion of clinical trials for PL8177 and PL9643, as well as the ability to secure partnerships and licensing agreements. Investors should conduct their own due diligence and consider their risk tolerance before investing in PTN.
What are the main risks for PTN?
Palatin Technologies, Inc. faces several risks, including competition from other pharmaceutical companies, regulatory hurdles and delays, unfavorable clinical trial results, reliance on Vyleesi for revenue, and limited financial resources. The company's success depends on the successful development and commercialization of its pipeline products. Clinical trial failures or regulatory setbacks could significantly impact the company's prospects. Additionally, Palatin needs to effectively compete with larger pharmaceutical companies and secure adequate funding to support its operations.
What revenue streams does Palatin Technologies, Inc. have in healthcare?
Palatin Technologies, Inc.'s primary revenue stream in healthcare currently comes from sales of Vyleesi, its approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. As the company's pipeline products progress through clinical development and potential regulatory approval, Palatin anticipates diversifying its revenue streams. Future revenue could be generated through sales of PL8177 for inflammatory bowel diseases (IBD) and PL9643 for dry eye disease, as well as through potential partnerships and licensing agreements with other pharmaceutical companies.
How does Palatin Technologies, Inc. navigate regulatory approval processes?
Palatin Technologies, Inc. navigates regulatory approval processes by conducting rigorous preclinical and clinical studies to demonstrate the safety and efficacy of its drug candidates. The company works closely with regulatory agencies, such as the FDA in the United States, to ensure compliance with all applicable regulations and guidelines. Palatin's regulatory strategy involves submitting comprehensive data packages, participating in advisory committee meetings, and addressing any questions or concerns raised by the regulatory agencies. The company's track record includes the successful FDA approval of Vyleesi.
What are the key factors to evaluate for PTN?
Palatin Technologies, Inc. (PTN) holds an AI score of 43/100 (low). Not financial advice.
How frequently does PTN data refresh on this page?
PTN prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PTN's recent stock price performance?
Palatin Technologies, Inc. (PTN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Approved product (Vyleesi) with established market presence. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide further insights.
- Financial data is based on the most recently available information.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.